The Centers for Medicare & Medicaid Services on Jan. 27 identified 15 high-spend medicines for the next round of price negotiations under the Inflation Reduction Act. The list includes inhalers, oncology agents, immunology biologics and the first Part B medicines to face IRA-enabled negotiations, notably GSK’s Anoro Ellipta, Gilead’s Bitkarvy, AbbVie’s Botox brands, Takeda’s Entyvio and Eli Lilly’s Trulicity and Verzenio. CMS said the selected drugs accounted for roughly $27 billion in Medicare spending over a recent 12‑month window and about 1.8 million Medicare users; new negotiated prices will take effect in early 2028 after the multi-step negotiation process.